Celltrion reveals Remsima clinical trial result on Crohn’s disease at DDW symposium
At the U.S. Digestive Disease Week(DDW) symposium at Chicago from the 6th to 9th of May, Celltrion revealed a result of the Remsima clinical trial(CT-P12 2.4 CD) on active Crohn’s disease patients and a result of the observational study on a large number of inflammatory bowel disease adult and pe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
